Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Progranulin Controls Cutting of Inclusion Protein
29 September 2007. Just over a year ago, two groups reported their findings that null mutations in the gene for the secreted growth factor progranulin are a frequent cause of frontotemporal dementia, particularly frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U, see ARF related news story). Shortly thereafter, other groups identified a major protein that makes up the inclusions found in FTLD-U (and in amyotrophic lateral sclerosis, ALS) as TDP-43, an obscure nuclear protein normally involved in exon splicing (see ARF related news story).

Progranulin and TDP-43 travel in different circles, and since their discovery, one obvious question has been how their paths might cross to cause neurodegeneration. In the September 26 Journal of Neuroscience, Leonard Petrucelli and colleagues from the Mayo Clinic College of Medicine in Jacksonville, Florida, report that decreasing progranulin expression leads to pathological processing of TDP-43 by caspases in cultured cells. Without progranulin, TDP-43 gets cleaved in a caspase-dependent manner, which can lead to translocation from its normal home in the nucleus to the cytosol.

The abnormal processing resembles what happens to TDP-43 in FTLD-U or ALS, the authors show, suggesting that loss of TDP-43 function due to inappropriate cleavage, translocation, or inclusion formation could play an important role in neurodegeneration.

To study the effects of progranulin on TDP-43 processing, first authors Yong-Jie Zhang and Ya-fei Xu used siRNA to knock down progranulin expression in HeLa epithelial cells and in H4 neuroglioma cells. In both cases, as progranulin levels fell, the scientists observed cleavage of TDP-43 into two insoluble fragments. The scientists implicated caspase 3 in the cleavage in several ways: they showed that progranulin knockdown resulted in increased caspase 3 activity in the cells, that caspase inhibitors blocked the proteolysis of TDP-43, and that treating TDP-43 in vitro with caspase 3 or caspase 7 generated similar fragments. The scientists concluded that suppressing progranulin expression is sufficient to trigger the breakdown of TDP-43 through a caspase-dependent mechanism.

The fragments produced in progranulin-deficient cells resembled those found in brains of FTLD-U patients, where TDP-43 relocates from the nucleus to cytoplasmic inclusions. Because of this, the investigators looked further at the consequences of TDP-43 cleavage on protein distribution in their cultured cells. Progranulin knockdown did not noticeably change TDP-43 distribution, whereas staurosporine, a stronger activator of caspase 3, was able to drive TDP-43 protein from its normal location in the nucleus out to the cytosol. That redistribution depended on caspase 3 cleavage, since it was blocked by a mutation in TDP-43 that destroyed a caspase cleavage site.

The effects of staurosporine mimic the change in TDP-43 distribution that occurs in FTLD-U and ALS, where the investigators observe an early loss of nuclear protein and accumulation of cytoplasmic staining, followed by accumulation of fibrillar inclusions in the cytosol.

The results do not show how a reduction in progranulin activity leads to caspase activation and TDP-43 cleavage. In addition, researchers need to determine if the shorter TDP-43 fragments are more fibrillogenic, a property that would explain the formation of inclusions. The intriguing supposition is that loss of progranulin leads to loss of functional TDP-43, which leads to cell death, but that, too, remains to be proven. Nonetheless, the authors envision using their cell culture models as screening tools to find other compounds that specifically affect the processing and redistribution of TDP-43.—Pat McCaffrey.

Reference:
Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, Pickering-Brown S, Dickson D, Petrucelli L. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci. 2007 Sep 26;27(39):10530-4. Abstract

 
Comments on News and Primary Papers
  Primary Papers: Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43.

Comment by:  George Perry (Disclosure)
Submitted 15 October 2007  |  Permalink Posted 16 October 2007
  I recommend this paper
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad